Zomedica Corp reported revenue of $6.13 million in Q2 2025, reflecting a YoY growth of 1.84% but a slight QoQ decrease of 2.09%. The company's gross profit margin has significantly declined to 38.9%, down from nearly 66% in the prior year, highlighting challenges in maintaining pricing power amidst rising costs and competitive pressures in the specialty drug manufacturing market. Management emphasized the importance of the TRUFORMA diagnostic platform as a strategic driver for future growth, particularly amid expanding market opportunities for veterinary care.
However, despite revenue growth, Zomedica posted a net loss of $23.93 million, showcasing deteriorating profitability as reflected in the negative earnings per share (EPS) of -$0.0244. Increased operational expenditures, especially in general and administrative costs, have conversely impacted the bottom line, prompting management to explore further operational efficiencies. Investors should closely monitor upcoming product launches and strategic partnerships, as these could influence Zomedica’s financial recovery trajectory.